Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2020

Open Access 01-12-2020 | Cholangiocarcinoma | Research

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

Authors: Takamichi Ishii, Takashi Ito, Shinji Sumiyoshi, Satoshi Ogiso, Ken Fukumitsu, Satoru Seo, Kojiro Taura, Shinji Uemoto

Published in: World Journal of Surgical Oncology | Issue 1/2020

Login to get access

Abstract

Background

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver carcinoma with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) components. We examined the clinicopathological characteristics and recurrence patterns of cHCC-CCA. Because of the rarity of cHCC-CCA, its etiology, clinicopathological features, and prognosis in comparison with other primary liver carcinoma remain unknown. Its recurrence pattern and sites in particular also need to be elucidated.

Methods

All patients who underwent hepatectomy for primary liver malignancies between 2005 and 2015 were retrospectively included in this study.

Results

Eight hundred and ninety-four hepatectomies were performed. Nineteen cases of cHCC-CCA (2.1%) in 16 patients were enrolled. Three patients underwent re-hepatectomy. The background of hepatitis viruses and tumor marker patterns of cHCC-CCA were similar to those of HCC and dissimilar to those of intrahepatic CCA (iCCA). Biliary invasion was common in cHCC-CCA and iCCA. The 5-year overall survival values of the cHCC-CCA, HCC, and iCCA patients were 44.7%, 56.6%, and 38.5%, respectively. The 5-year recurrence-free survival values of the cHCC-CCA, HCC, and iCCA patients were 12.2%, 28.7%, and 32.9%, respectively. The liver was the most common recurrence site. Unlike HCC, however, the lymph node was the second-most common recurrence site in both cHCC-CCA and iCCA. Pathological samples of the recurrent lesions were obtained in six patients, and four had cHCC-CCA recurrence pathologically.

Conclusion

cHCC-CCA had a mixture of characteristics of HCC and iCCA. Many cases of cHCC-CCA remained cHCC-CCA pathologically even after recurrence.
Literature
1.
go back to reference Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In: Digestive system Tumours. WHO classification of Tumours, vol. 1. 5th ed. France: International Agency for Research on Cancer Press; 2019. p. 260–2. Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In: Digestive system Tumours. WHO classification of Tumours, vol. 1. 5th ed. France: International Agency for Research on Cancer Press; 2019. p. 260–2.
3.
go back to reference Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68:113–26.CrossRef Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68:113–26.CrossRef
4.
go back to reference Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.CrossRef Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.CrossRef
5.
go back to reference Ariizumi S, Kotera Y, Katagiri S, Nakano M, Yamamoto M. Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor. Ann Surg Oncol. 2012;19:1628–36.CrossRef Ariizumi S, Kotera Y, Katagiri S, Nakano M, Yamamoto M. Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor. Ann Surg Oncol. 2012;19:1628–36.CrossRef
6.
go back to reference Itoh S, Ikegami T, Yoshizumi T, Wang H, Takeishi K, et al. Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma. Anticancer Res. 2015;35:2475–6.PubMed Itoh S, Ikegami T, Yoshizumi T, Wang H, Takeishi K, et al. Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma. Anticancer Res. 2015;35:2475–6.PubMed
7.
go back to reference Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2019;6:11–21.CrossRef Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2019;6:11–21.CrossRef
8.
go back to reference Wakizaka K, Yokoo H, Kamiyama T, Ohira M, Kato K, et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol. 2019;34:1074–80.CrossRef Wakizaka K, Yokoo H, Kamiyama T, Ohira M, Kato K, et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol. 2019;34:1074–80.CrossRef
9.
go back to reference Wang AQ, Zheng YC, Du J, Zhu CP, Huang HC, et al. Combined hepatocellular cholangiocarcinoma: controversies to be addressed. World J Gastroenterol. 2016;22:4459–65.CrossRef Wang AQ, Zheng YC, Du J, Zhu CP, Huang HC, et al. Combined hepatocellular cholangiocarcinoma: controversies to be addressed. World J Gastroenterol. 2016;22:4459–65.CrossRef
10.
go back to reference Wang J, Li E, Yang H, Wu J, Lu HC, et al. Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends. World J Surg Oncol. 2019;17:43.CrossRef Wang J, Li E, Yang H, Wu J, Lu HC, et al. Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends. World J Surg Oncol. 2019;17:43.CrossRef
11.
go back to reference Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol. 2012;19:2869–76.CrossRef Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol. 2012;19:2869–76.CrossRef
12.
go back to reference De Vito C, Sarker D, Ross P, Heaton N, Quaglia A. Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series. Virchows Arch. 2017;471:619–29.CrossRef De Vito C, Sarker D, Ross P, Heaton N, Quaglia A. Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series. Virchows Arch. 2017;471:619–29.CrossRef
13.
go back to reference Ito T, Ishii T, Sumiyoshi S, Ogiso S, Fukumitsu K, et al. Living donor liver transplantation for combined hepatocellular-cholangiocarcinoma: a case series of four patients. Int J Surg Case Rep. 2020;74:46–52.CrossRef Ito T, Ishii T, Sumiyoshi S, Ogiso S, Fukumitsu K, et al. Living donor liver transplantation for combined hepatocellular-cholangiocarcinoma: a case series of four patients. Int J Surg Case Rep. 2020;74:46–52.CrossRef
14.
go back to reference Ishii T, Hatano E, Yasuchika K, Taura K, Seo S, et al. High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter. Surg Today. 2014;44:1900–5.CrossRef Ishii T, Hatano E, Yasuchika K, Taura K, Seo S, et al. High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter. Surg Today. 2014;44:1900–5.CrossRef
15.
go back to reference Ishii T, Fukumitsu K, Ogawa E, Okamoto T. Uemoto S living donor liver transplantation in situs inversus totalis with a patient-specific three-dimensional printed liver model. Pediatr Transplant. 2020;1:e13675. Ishii T, Fukumitsu K, Ogawa E, Okamoto T. Uemoto S living donor liver transplantation in situs inversus totalis with a patient-specific three-dimensional printed liver model. Pediatr Transplant. 2020;1:e13675.
16.
go back to reference Ishii T, Hatano E, Furuyama H, Manaka D, Terajima H, et al. Preventive measures for postoperative bile leakage after central hepatectomy: a multicenter, prospective, observational study of 101 patients. World J Surg. 2016;40:1720–8.CrossRef Ishii T, Hatano E, Furuyama H, Manaka D, Terajima H, et al. Preventive measures for postoperative bile leakage after central hepatectomy: a multicenter, prospective, observational study of 101 patients. World J Surg. 2016;40:1720–8.CrossRef
17.
go back to reference Yoh T, Hatano E, Seo S, Terajima H, Uchida T, et al. Preoperative criterion identifying a low-risk group for lymph node metastasis in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2018;25:299–307.CrossRef Yoh T, Hatano E, Seo S, Terajima H, Uchida T, et al. Preoperative criterion identifying a low-risk group for lymph node metastasis in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2018;25:299–307.CrossRef
18.
go back to reference Wu CH, Yong CC, Liew EH, Tsang LL, Lazo M, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: diagnosis and prognosis after resection or transplantation. Transplant Proc. 2016;48:1100–4.CrossRef Wu CH, Yong CC, Liew EH, Tsang LL, Lazo M, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: diagnosis and prognosis after resection or transplantation. Transplant Proc. 2016;48:1100–4.CrossRef
19.
go back to reference Yu XH, Xu LB, Zeng H, Zhang R, Wang J, et al. Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2011;10:620–5.CrossRef Yu XH, Xu LB, Zeng H, Zhang R, Wang J, et al. Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2011;10:620–5.CrossRef
20.
go back to reference Futsukaichi Y, Tajiri K, Kobayashi S, Nagata K, Yasumura S, et al. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature. Clin J Gastroenterol. 2019;12:128–34.CrossRef Futsukaichi Y, Tajiri K, Kobayashi S, Nagata K, Yasumura S, et al. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature. Clin J Gastroenterol. 2019;12:128–34.CrossRef
21.
go back to reference Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci. 2018;109:2549–57.CrossRef Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci. 2018;109:2549–57.CrossRef
22.
go back to reference Trikalinos NA, Zhou A, Doyle MBM, Fowler KJ, Morton A, et al. Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience. J Natl Compr Cancer Netw. 2018;16:1193–9.CrossRef Trikalinos NA, Zhou A, Doyle MBM, Fowler KJ, Morton A, et al. Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience. J Natl Compr Cancer Netw. 2018;16:1193–9.CrossRef
23.
go back to reference Tian MX, Luo LP, Liu WR, Deng W, Yin JC, et al. Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma. Cancer Manag Res. 2019;11:5187–95.CrossRef Tian MX, Luo LP, Liu WR, Deng W, Yin JC, et al. Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma. Cancer Manag Res. 2019;11:5187–95.CrossRef
24.
go back to reference Wang Y, Yang Q, Li S, Luo R, Mao S, et al. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. Clin Radiol. 2019;74:407.e401.CrossRef Wang Y, Yang Q, Li S, Luo R, Mao S, et al. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. Clin Radiol. 2019;74:407.e401.CrossRef
25.
go back to reference Ye J, Xie X, Lin Y, Liu B, Wang W, et al. Imaging features of combined hepatocellular-cholangiocarcinoma on contrast-enhanced ultrasound: correlation with clinicopathological findings. Clin Radiol. 2018;73:237–43.CrossRef Ye J, Xie X, Lin Y, Liu B, Wang W, et al. Imaging features of combined hepatocellular-cholangiocarcinoma on contrast-enhanced ultrasound: correlation with clinicopathological findings. Clin Radiol. 2018;73:237–43.CrossRef
26.
go back to reference Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16:623–9.CrossRef Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16:623–9.CrossRef
Metadata
Title
Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
Authors
Takamichi Ishii
Takashi Ito
Shinji Sumiyoshi
Satoshi Ogiso
Ken Fukumitsu
Satoru Seo
Kojiro Taura
Shinji Uemoto
Publication date
01-12-2020
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2020
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-020-02099-w

Other articles of this Issue 1/2020

World Journal of Surgical Oncology 1/2020 Go to the issue